Related Experiment Video
Updated: Jul 31, 2025

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
Published on: November 4, 2021
Pembrolizumab induced pericardial tamponade: A case report
Dariusz Uczkowski1,2, Hamza Ashraf1,2, Arunabh Sekhri1,2
1Overlook Medical Center Atlantic Health System Summit New Jersey USA.
Key Clinical Message:
The occurrence of a large pericardial effusion is not a commonly noted adverse event associated with pembrolizumab and our report demonstrates that a rapid development can be diagnosed with close monitoring and triage to acute medical settings.
Abstract:
Pembrolizumab is an immune checkpoint inhibitor used in various types of cancers. Pericardial tamponade is a rare side effect reported in only very few case reports. Early recognition and therapeutic intervention is vital in all cases. We report a case of a 54-year-old male with Stage 3 lung adenocarcinoma who developed cardiac tamponade secondary to pembrolizumab and subsequently required pericardial window.
More Related Videos
Related Concept Videos
Pericarditis III: Medical Management
Pericarditis II: Clinical Features and Diagnostic Tests
Pericarditis IV: Nursing Management
Pericarditis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.

